Background: We conducted a prospective observational study for investigating the changes in the 13th member of a disintegrin-like and metalloprotease with thrombospondin type 1 motif (ADAMTS13) and its association with the coagulofibrinolytic response in adult trauma patients.
Methods: In 39 trauma patients hospitalized for longer than 7 days, time-course changes in biomarkers of coagulofibrinolysis and systemic inflammation along with ADAMTS13 activity were examined. The patients were stratified into three groups based on ADAMTS13 activities on admission (day 0): normal group (≥70%), mildly decreased group (≥50 and < 70%) and moderately decreased group (< 50%).
Results: Among 39 patients with a median Injury Severity Score (ISS) of 20, 11 patients developed disseminated intravascular coagulation (DIC) and 16 patients required transfusion. Six of 39 patients (15.4%) showed moderate decreased ADAMTS13 activity to < 50%, and 20 patients (51.3%) showed mild drops (≥50 and < 70%). These changes in ADAMTS13 activity on day 0 were significantly correlated with changes in IL-6 and other coagulofibrinolytic markers such as platelet counts, prothrombin time and fibrin/fibrinogen degradation product (FDP). Antithrombin activity (AT) and serum albumin (Alb) level showed significantly positive linear correlations with ADAMTS13 activity (AT: r = 0.513, p < 0.001; Alb: r = 0.647, p < 0.001). Simple logistic regression analyses showed that ADAMTS13 activity, if less than 50%, was significantly correlated with the development of DIC (OR 7.499, 95%CI 1.121-49.242, p = 0.038) and the need for transfusion of fresh frozen plasma (OR 9.000, 95%CI 1.327-61.025, p = 0.028).
Conclusions: ADAMTS13 activity decreased even in the early phase of trauma, which was complicated by coagulopathy and systemic inflammation. Furthermore, the decrease in ADAMTS13 activity was correlated with DIC and plasma transfusion.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953673 | PMC |
| http://dx.doi.org/10.1186/s12959-021-00270-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Retrospective Audit on the Use of the TechnoClone TECHNOSCREEN ADAMTS-13 Assay in the Diagnostic Process for Thrombotic Thrombocytopenic Purpura at LabPlus, New Zealand.
Int J Lab Hematol
December 2024
LabPLUS, Auckland City Hospital, Auckland, New Zealand.
Introduction: The TECHNOSCREEN ADAMTS-13 assay (ADSC) is a new lateral flow test which is simple and quick to perform, with a high negative predictive value (NPV); it may improve the diagnostic workflow for TTP. LabPlus in Auckland, New Zealand, performs all ADAMTS13 tests in the Auckland and Northland regions. The ADSC was used at LabPlus between 2022 and 2023 as part of a protocol where results of 0 IU/mL and 0.
View Article and Find Full Text PDFEvaluating the potential for iodinated radiocontrast agents to interfere with ADAMTS13 activity testing via fluorescence resonance energy transfer methodology.
Am J Clin Pathol
December 2024
Special Coagulation Laboratory, Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, US.
Objectives: Fluorescence resonance energy transfer (FRET)-based ADAMTS13 activity assays are critical for the diagnosis of thrombotic thrombocytopenic purpura. However, these assays are susceptible to interference. As iodide has been suggested to interfere in laboratory testing via fluorophore quenching or promotion, we aimed to determine whether iodinated contrast (Omnipaque) interferes with the ATS-13 ADAMTS13 Activity Assay 2.
View Article and Find Full Text PDFA novel automated chemiluminescent enzyme immunoassay (CLEIA) for ADAMTS13 activity enables accompanying measurements of the inhibitory autoantibodies.
J Thromb Haemost
December 2024
Department of Hematology, Nara Medical University, Kashihara, Japan; Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan. Electronic address:
Background: Thrombotic thrombocytopenic purpura (TTP) is a fatal disease caused by severe deficiency in ADAMTS13 activity. ADAMTS13 activity measurement is essential for the diagnosis of TTP, but conventional standard assays are manual and time-consuming. Automated ADAMTS13 activity assays have recently become available; however, their accuracy remains challenging.
View Article and Find Full Text PDFMechanistic insight into multiple antibody binding to ADAMTS13 in immune thrombotic thrombocytopenic purpura.
Res Pract Thromb Haemost
October 2024
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Article Synopsis
- Antibody-mediated inhibition of ADAMTS-13, a protein critical for blood clotting, leads to immune thrombotic thrombocytopenic purpura (iTTP), but the impact of multiple antibodies on this process is not fully understood.
- The study examines how different antibodies interact with ADAMTS-13 and finds that while both stimulatory and inhibitory antibodies can bind simultaneously, the inhibition prevails when both are present.
- Results suggest that these antibodies modify ADAMTS-13's catalytic activity through allosteric changes, indicating potential pathways for developing new diagnostic and therapeutic strategies for managing iTTP.
Increased Platelet Adhesiveness in Patients with Venous Thromboembolic Disease.
TH Open
October 2024
Thrombosis and Haemostasis Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Association between global platelet function and the risk of venous thromboembolic disease (VTE) has been proposed, though the mechanisms do not involve increased platelet aggregation. However, platelet adhesiveness has not been systematically explored in VTE patients. To evaluate platelet adhesive functions in VTE patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!